BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05)."As we progress through 2019 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE